Related Experiment Video
Updated: Jan 9, 2026
Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine
Published on: November 4, 2018
FDA Approves First Targeted Treatment for Cerebrotendinous Xanthomatosis: A Perspective on a Landmark in Rare Lipid
Laiba Jalal1, Areeba Aamir Ali Basaria1, Hermann Yokolo2
1Dow University of Health Sciences Karachi Pakistan.
Background And Aims:
Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive disorder caused by mutations in the CYP27A1 gene, leading to deficient sterol 27-hydroxylase activity. This enzyme is critical for bile acid synthesis, and its dysfunction results in reduced chenodeoxycholic acid (CDCA) levels and subsequent accumulation of cholestanol in tissues. This study highlights the recent FDA approval of Ctexli (chenodiol), a synthetic CDCA formulation, as the first treatment option for CTX.
Methods:
A comprehensive literature search was performed using PubMed and Google Scholar, and relevant articles were identified that focused on the mechanism of action, clinical efficacy, and safety of chenodiol.
Results:
Data from the RESTORE Phase 3 trial demonstrated that chenodiol significantly reduced plasma cholestanol and urinary bile alcohol levels, with the most pronounced results observed in patients treated before the onset of irreversible neurological damage. The FDA approval of Ctexli validated these findings and established chenodiol as a reliable therapeutic option for CTX.
Conclusion:
The FDA approval of chenodiol marks a significant milestone in the management of CTX, providing a standardized and evidence-based therapy for a previously neglected condition. Early diagnosis, broader screening, and global access to the drug will be key to improving outcomes and ensuring lasting clinical benefit.
Insights
Cerebrotendinous xanthomatosis (CTX) treatment now includes chenodiol (Ctexli), a synthetic bile acid. This FDA-approved therapy effectively lowers cholestanol levels, offering new hope for patients with this rare genetic disorder.
Area of Science:
- Biochemistry
- Genetics
- Pharmacology
Background:
- Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive disorder.
- It stems from CYP27A1 gene mutations, impairing sterol 27-hydroxylase activity.
- This leads to altered bile acid synthesis and cholestanol accumulation.
Purpose of the Study:
- To review the mechanism of action, efficacy, and safety of chenodiol for CTX.
- To highlight the significance of the recent FDA approval of Ctexli (chenodiol).
Main Methods:
- Comprehensive literature search using PubMed and Google Scholar.
- Identification of relevant articles on chenodiol's action, efficacy, and safety.
Main Results:
- Chenodiol significantly reduced plasma cholestanol and urinary bile alcohol levels in the RESTORE Phase 3 trial.
- Early treatment with chenodiol showed the most pronounced benefits, especially before neurological damage.
- FDA approval of Ctexli validates chenodiol as a reliable CTX therapeutic option.
Conclusions:
- FDA approval of chenodiol represents a major advancement in CTX management.
- Chenodiol offers a standardized, evidence-based therapy for CTX.
- Early diagnosis, screening, and drug access are crucial for improving patient outcomes.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:22Lysosomal Hydrolases
01:26FDA Approved Drugs: Changes to Approved Drugs